---
title: 'Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic
  acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer
  (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase
  2 trial'
date: '2025-01-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39802302/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250113171006&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: The PanaMa trial aimed to compare the efficacy of 5-fluorouracil
  and folinic acid (FU/FA) ± panitumumab maintenance in untreated RAS wild-type metastatic
  colorectal cancer (mCRC) ...'
disable_comments: true
---
BACKGROUND: The PanaMa trial aimed to compare the efficacy of 5-fluorouracil and folinic acid (FU/FA) ± panitumumab maintenance in untreated RAS wild-type metastatic colorectal cancer (mCRC) ...